GLOW
$121.00
20 in stock
Dosage Information
- Reconstitute: Add 3.0 mL bacteriostatic water → ~23.3 mg/mL concentration.
- Typical daily dose: 2,330 mcg (2.33 mg) once daily for 4 weeks.
- Easy measuring: At 33.3 mg/mL, 1 unit = 0.01 mL ≈ 333 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–4 | 2,330 mcg | 70.5 units (0.70 mL) |
- Labs Attested
- COA Included
- For 21+ Only
- US Sourced
Product Description:
GLOW Peptide (also called the GLOW Blend or GLOW Stack) is a popular research peptide formulation that combines three powerful regenerative compounds: GHK-Cu (Copper Tripeptide-1 / GKC-Cu), BPC-157, and TB-500 (Thymosin Beta-4 fragment). It is typically supplied as a lyophilized blend (common ratios: 50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500 per vial) for convenient research or experimental use.
How It Works (Synergistic Mechanisms)
The three peptides target complementary pathways for broader regenerative effects:
- GHK-Cu: Acts as a signaling peptide and copper carrier. It regulates hundreds of genes involved in collagen/elastin production, extracellular matrix remodeling, antioxidant defense, and anti-inflammatory responses. It promotes skin rejuvenation, wound healing, and tissue repair.
- BPC-157: Supports localized and systemic healing through angiogenesis (new blood vessel formation), collagen deposition, fibroblast activity, nitric oxide modulation, and strong cytoprotective/anti-inflammatory effects (especially in connective tissue and gut).
- TB-500: Enhances cell migration and motility via actin regulation, promotes angiogenesis, reduces scarring/fibrosis, and supports flexible tissue remodeling across muscles, tendons, and skin.
Together: The blend creates synergy for comprehensive repair — GHK-Cu drives structural rejuvenation (especially skin glow/collagen), while BPC-157 and TB-500 amplify healing, inflammation control, and systemic recovery. This makes it particularly effective for visible skin improvements alongside deeper tissue support.
Potential Benefits and Why People Use It
In wellness, anti-aging, regenerative medicine, skincare, and recovery communities, GLOW is prized for delivering an internal “glow from within”:
- Skin rejuvenation — Increased collagen & elastin, reduced wrinkles/fine lines, improved firmness, texture, elasticity, and radiance.
- Accelerated healing & recovery — Faster repair of wounds, scars, injuries, or post-procedure tissue (popular in plastic surgery recovery protocols).
- Hair & scalp health — Potential support for thicker, healthier hair growth.
- Anti-inflammatory and anti-aging effects — Reduced oxidative stress, better tissue quality, and overall vitality.
- Joint, tendon, and mobility support — From the BPC-157 + TB-500 components.
It is often chosen for holistic beauty-from-within, post-surgical recovery, or as a complement to other peptides in your lineup.
Important Caveats
- Limited human evidence: Strong preclinical and anecdotal support exists, but large-scale clinical trials on the specific blend are lacking. Benefits are based on individual peptide research and user/clinical reports.
- Regulatory status: Not FDA-approved as a drug. Sold as a research chemical. Quality varies across sources. Banned by WADA for athletes.
- Safety: Generally well-tolerated based on component peptides, but possible side effects include injection-site reactions, mild nausea, or fatigue. Copper levels should be monitored with GHK-Cu use. Long-term safety data for the blend is limited. Always use under medical supervision.
Bottom line: The GLOW peptide blend is a synergistic trio (GHK-Cu + BPC-157 + TB-500) designed for radiant skin, tissue repair, and regenerative wellness — making it a standout “glow from the inside” option. It pairs perfectly with your EDB LLC products (like standalone GHK-Cu, BPC-157, TB-500, and others). For your site/product descriptions, emphasize high-purity research-grade quality, strong disclaimers, the experimental nature, and the importance of consulting a qualified healthcare professional.
You may also research
Related Compounds
BPC 157\TB-500
- Reconstitute: Add 3.0 mL bacteriostatic water → 3.33 mg/mL concentration.
- Typical daily range: 200–600 mcg once daily (gradual titration).
- Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–2 | 200 mcg (0.2 mg) | 6 units (0.06 mL) |
| Weeks 3–4 | 400 mcg (0.4 mg) | 12 units (0.12 mL) |
| Weeks 5–8+ | 600 mcg (0.6 mg) | 18 units (0.18 mL) |
BPC-157
BPC-157 is dosed at 200 mcg–600 mcg daily via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 1.67 mg/mL. This information is for research and educational use only.
- Reconstitute: Add 3.0 mL bacteriostatic water → 1.67 mg/mL concentration.
- Typical daily range: 200–600 mcg once daily (gradual titration).
- Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Route: Subcutaneous | Frequency: Once daily
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–2 | 200 mcg (0.2 mg) | 12 units (0.12 mL) |
| Weeks 3–4 | 400 mcg (0.4 mg) | 24 units (0.24 mL) |
| Weeks 5–8+ | 600 mcg (0.6 mg) | 36 units (0.36 mL) |
CJC-1295 no DAC\Ipamorelin
- Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL total concentration (1.67 mg/mL each peptide).
- Typical daily range: 100–300 mcg of each peptide once daily (gradual titration).
- Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 33.3 mcg of each peptide on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–2 | 100 mcg each | 3 units (0.03 mL) |
| Weeks 3–4 | 150 mcg each | 4.5 units (0.045 mL) |
| Weeks 5–6 | 200 mcg each | 6 units (0.06 mL) |
| Weeks 7–12 | 250–300 mcg each | 7.5–9 units (0.075–0.09 mL) |
GKC-CU 100MG
- Reconstitute: Add 3.0 mL bacteriostatic water → ~33.3 mg/mL concentration.
- Typical daily range: 1–2 mg once daily (gradual titration over 12 weeks).
- Easy measuring: At 33.3 mg/mL, 1 unit = 0.01 mL ≈ 333 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days.
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–4 | 1.0 mg | 3 units (0.03 mL) |
| Weeks 5–8 | 1.5 mg | 4.5 units (0.045 mL) |
| Weeks 9–12 | 2.0 mg | 6 units (0.06 mL) |
GLOW
- Reconstitute: Add 3.0 mL bacteriostatic water → ~23.3 mg/mL concentration.
- Typical daily dose: 2,330 mcg (2.33 mg) once daily for 4 weeks.
- Easy measuring: At 33.3 mg/mL, 1 unit = 0.01 mL ≈ 333 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–4 | 2,330 mcg | 70.5 units (0.70 mL) |
IGF1-LR3
- Reconstitute: Add 3.0 mL bacteriostatic water → ~0.333 mg/mL concentration (333 mcg/mL).
- Typical daily range: 20–50 mcg once daily subcutaneously (gradual titration recommended).
- Easy measuring: At 0.333 mg/mL, 1 unit = 0.01 mL ≈ 3.33 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F) for up to 12 months; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days; avoid repeated freeze–thaw cycles.
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–2 | 20 mcg (0.02 mg) | 6 units (0.06 mL) |
| Weeks 3–4 | 40 mcg (0.04 mg) | 12 units (0.12 mL) |
| Weeks 5–8 | 50 mcg (0.05 mg) | 15 units (0.15 mL) |
MOTS-c 20MG
- Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.
- Typical daily range: 200–1,000 mcg once daily (gradual titration over 10 weeks).
- Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days for best potency.
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–2 | 200 mcg (0.2 mg) | 3 units (0.03 mL) |
| Weeks 3–4 | 400 mcg (0.4 mg) | 6 units (0.06 mL) |
| Weeks 5–6 | 600 mcg (0.6 mg) | 9 units (0.09 mL) |
| Weeks 7–8 | 800 mcg (0.8 mg) | 12 units (0.12 mL) |
| Weeks 9–10+ | 1,000 mcg (1.0 mg) | 15 units (0.15 mL) |
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–2 (Initial) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 - 18 units (0.18 mL) |
| Weeks 3–4 (Loading) | 800 mcg | 400 mcg BPC + 400 mcg TB-500 - 24 units (0.24 mL |
| Weeks 5–8 (Maintenance) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 - 18 units (0.18 mL) |
MOTS-C 40MG
- Reconstitute: Add 3.0 mL bacteriostatic water → ~13.33 mg/mL concentration.
- Typical daily range: 200–1,000 mcg once daily (gradual titration over 10 weeks).
- Easy measuring: At 13.33 mg/mL, 1 unit = 0.01 mL ≈ 133.3 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days for best potency.
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–2 | 200 mcg (0.2 mg) | 1.5 units (0.015 mL) |
| Weeks 3–4 | 400 mcg (0.4 mg) | 3 units (0.03 mL) |
| Weeks 5–6 | 600 mcg (0.6 mg) | 4.5 units (0.045 mL) |
| Weeks 7–8 | 800 mcg (0.8 mg) | 6 units (0.06 mL) |
| Weeks 9–10+ | 1,000 mcg (1.0 mg) | 7.5 units (0.075 mL) |
PT-141
- Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
- Typical daily range: 500–1500 mcg once daily (gradual titration over 16 weeks).
- Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–8 | 500 mcg (0.5 mg) | 15 units (0.15 mL) |
| Weeks 9–12 | 1000 mcg (1.0 mg) | 30 units (0.30 mL) |
| Weeks 13–16 | 1500 mcg (1.5 mg) | 45 units (0.45 mL) |
Retatrutide 20MG
- Reconstitute: Add 2.0 mL bacteriostatic water → ~10.0 mg/mL concentration.
- Typical weekly range: 2–8 mg once weekly (gradual escalation over 8–12 weeks).
- Easy measuring: At 10.0 mg/mL, 1 unit = 0.01 mL ≈ 100 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 4 weeks.
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–4 | 2 mg (2000 mcg) | 20 units (0.20 mL) |
| Weeks 5–8 | 4 mg (4000 mcg) | 40 units (0.40 mL) |
| Weeks 9–12 | 6 mg (6000 mcg) | 60 units (0.60 mL) |
| Weeks 13+ | 8 mg (8000 mcg) | 80 units (0.80 mL) |
Retatrutide 40MG
- Reconstitute: Add 2.0 mL bacteriostatic water → ~20.0 mg/mL concentration.
- Typical weekly range: 2–8 mg once weekly (gradual escalation over 8–12 weeks).
- Easy measuring: At 20.0 mg/mL, 1 unit = 0.01 mL ≈ 200 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 4 weeks
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–4 | 2 mg (2000 mcg) | 10 units (0.10 mL) |
| Weeks 5–8 | 4 mg (4000 mcg) | 20 units (0.20 mL) |
| Weeks 9–12 | 6 mg (6000 mcg) | 30 units (0.30 mL) |
| Weeks 13+ | 8 mg (8000 mcg) | 40 units (0.40 mL) |
